AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AEON Biopharma (NYSE American: AEON) priced an upsized underwritten public offering for expected gross proceeds of approximately $13.75 million, with potential total proceeds of up to about $43.3 million if all accompanying milestone warrants are exercised in cash.
The offering comprises 42,688,606 shares of common stock (or pre-funded warrants) at a combined public offering price of $0.3221 per share and two milestone warrants (or $0.3220 per pre-funded warrant package). Each package includes one two-year milestone warrant with a $0.3221 exercise price and one five-year milestone warrant with a $0.3704 exercise price, all immediately exercisable. AEON granted a 30-day over-allotment option for up to 6,403,290 additional shares and/or milestone warrants. Closing is expected on or about July 15, 2026, subject to customary conditions, and proceeds are intended for working capital and comparative analytical testing of ABP-450 to support its biosimilarity to BOTOX.
Positive
- $13.75 million expected gross proceeds from underwritten public offering
- Milestone warrants could add up to $29.6 million in cash proceeds
- Offering package covers 42.7 million shares or pre-funded warrants
- Use of proceeds includes ABP-450 biosimilarity testing to BOTOX
Negative
- Issuance of 42.7 million shares may significantly dilute existing shareholders
- Over-allotment option adds up to 6.4 million additional shares and warrants
- Two- and five-year milestone warrants create potential future equity overhang
Details
News Market Reaction – AEON
On Jul 14, the day this news came out, AEON closed 10.84% above the previous close. Argus tracked a trough of -50.1% from its starting point during tracking. Our momentum scanner recorded 102 alerts for this stock that day. That session’s volume was 55.5x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jul 14 session.
Key Figures
- Base offering size
- $13.75 million
- Expected gross proceeds from underwritten public offering
- Potential warrant proceeds
- $29.6 million
- Additional gross proceeds if all milestone warrants exercised in cash
- Maximum gross proceeds
- $43.3 million
- Total gross proceeds combining base offering and full warrant exercise
- Shares in offering
- 42,688,606 shares
- Common stock or pre-funded warrants sold with milestone warrants
- Offering price
- $0.3221 per share
- Combined price per common share with two milestone warrants
- Pre-funded unit price
- $0.3220 per pre-funded warrant
- Combined price per pre-funded warrant with two milestone warrants
- Pre-funded exercise price
- $0.0001 per share
- Exercise price for each pre-funded warrant
- Two-year warrant strike
- $0.3221 per share
- Exercise price of two-year milestone warrants
Previous Offering Reports
-
Closed $20.0M underwritten public offering of common units with warrants attached.
-
Priced $20.0M underwritten public offering of common and pre-funded units.
-
Launched proposed public offering of common stock or pre-funded warrants plus warrants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pre-funded warrant financial
milestone warrant financial
registration statement regulatory
form s-1 regulatory
rule 462(b) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately
The offering consists of 42,688,606 shares of common stock of the Company (or pre-funded warrants in lieu thereof), with each share of common stock or pre-funded warrant accompanied by one two-year milestone warrant to purchase one share of common stock (or one pre-funded warrant in lieu thereof) and one five-year milestone warrant to purchase one share of common stock (or one pre-funded warrant in lieu thereof). The combined public offering price is
The gross proceeds to the Company from this offering are expected to be approximately
The offering is expected to close on or about July 15, 2026, subject to satisfaction or waiver of customary closing conditions.
The proceeds from this offering are expected to be used for working capital and general corporate purposes, including conducting comparative analytical testing on ABP-450 to support biosimilarity to BOTOX®.
Lake Street Capital Markets, LLC is acting as the sole bookrunner for this offering. Laidlaw & Company (UK) Ltd. is acting as lead manager for the offering.
A Registration Statement on Form S-1 (File No. 333-297327), as amended, relating to the securities was initially filed with the Securities and Exchange Commission (“SEC”) on July 8, 2026 and was declared effective on July 13, 2026, and a related registration statement was filed with the SEC on July 13, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and became automatically effective upon filing (together, the “Registration Statement”). This offering is being made only by means of a preliminary prospectus forming a part of the Registration Statement and a final prospectus. The Registration Statement and the preliminary prospectus relating to the offering are available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus, when available, may be obtained from Lake Street Capital Markets, LLC, 121 S 8th St Suite 1000, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company advancing ABP-450 as a proposed biosimilar to BOTOX® for therapeutic indications. The U.S. therapeutic neurotoxin market exceeds
Forward Looking Statements
This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "expect," "anticipate," "intend," "believe," "estimate," "will," and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to: expectations regarding the completion of the offering and the use of proceeds thereof; the Company's ability to achieve the milestones underlying the two-year and five-year milestone warrants; the Company's ability to advance ABP-450 through the Section 351(k) biosimilar pathway; the Company's ability to maintain compliance with the continued listing standards of the NYSE American; the Company's ability to complete its preclinical and clinical studies; and changes in local or national economic conditions. This list of risks, uncertainties, and other factors is not complete. Any or all forward-looking statements the Company makes may turn out to be wrong. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com
Source: AEON Biopharma
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.